
[OneMedForum] Clarient Grows Along with Cancer Testing Market
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
The 160,000 square-foot facility could bring at least 300 jobs to Georgia.
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Some patients fear injections so much that they avoid getting proper medical treatment, sometimes with life-threatening results. Transdermal patches, which administer drugs through the skin, could make the bite of the needle a mere unpleasant memory.
Copyright © 2025 | WordPress Theme by MH Themes